Stack Financial Management Inc Has $20.99 Million Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Stack Financial Management Inc decreased its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 1.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 90,702 shares of the medical research company’s stock after selling 1,241 shares during the period. IQVIA comprises 2.4% of Stack Financial Management Inc’s holdings, making the stock its 17th largest holding. Stack Financial Management Inc’s holdings in IQVIA were worth $20,987,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. AdvisorNet Financial Inc boosted its position in shares of IQVIA by 327.6% during the 4th quarter. AdvisorNet Financial Inc now owns 124 shares of the medical research company’s stock worth $29,000 after acquiring an additional 95 shares in the last quarter. BKM Wealth Management LLC acquired a new stake in IQVIA in the fourth quarter valued at approximately $32,000. Activest Wealth Management acquired a new stake in IQVIA in the fourth quarter valued at approximately $35,000. CVA Family Office LLC acquired a new stake in IQVIA in the fourth quarter valued at approximately $43,000. Finally, CoreFirst Bank & Trust acquired a new stake in IQVIA in the third quarter valued at approximately $44,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Trading Up 0.6 %

Shares of IQV traded up $1.36 during trading hours on Friday, reaching $235.34. 270,564 shares of the company traded hands, compared to its average volume of 964,479. The firm has a market cap of $42.71 billion, a price-to-earnings ratio of 32.11, a PEG ratio of 2.33 and a beta of 1.50. IQVIA Holdings Inc. has a 12-month low of $167.42 and a 12-month high of $261.73. The company has a current ratio of 0.86, a quick ratio of 0.86 and a debt-to-equity ratio of 2.12. The stock’s fifty day moving average price is $245.35 and its 200 day moving average price is $222.77.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.84 EPS for the quarter, topping the consensus estimate of $2.82 by $0.02. IQVIA had a return on equity of 29.32% and a net margin of 9.06%. The business had revenue of $3.87 billion for the quarter, compared to analyst estimates of $3.80 billion. During the same quarter in the prior year, the firm posted $2.54 EPS. The business’s quarterly revenue was up 3.5% compared to the same quarter last year. Sell-side analysts forecast that IQVIA Holdings Inc. will post 10.11 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. UBS Group lifted their target price on shares of IQVIA from $240.00 to $300.00 and gave the stock a “buy” rating in a research note on Thursday, February 15th. StockNews.com upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a report on Friday, February 16th. Truist Financial boosted their price target on shares of IQVIA from $286.00 to $297.00 and gave the stock a “buy” rating in a report on Tuesday, February 27th. Guggenheim cut shares of IQVIA from a “buy” rating to a “neutral” rating in a research note on Thursday, February 15th. Finally, Leerink Partnrs reiterated an “outperform” rating on shares of IQVIA in a research note on Monday, February 26th. Three research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $256.80.

Insiders Place Their Bets

In related news, insider Eric Sherbet sold 1,000 shares of the firm’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $241.50, for a total transaction of $241,500.00. Following the completion of the sale, the insider now directly owns 20,836 shares of the company’s stock, valued at approximately $5,031,894. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other IQVIA news, insider Kevin C. Knightly sold 8,607 shares of the business’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total value of $2,153,213.19. Following the completion of the sale, the insider now owns 5,251 shares in the company, valued at $1,313,642.67. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Eric Sherbet sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $241.50, for a total value of $241,500.00. Following the sale, the insider now owns 20,836 shares of the company’s stock, valued at approximately $5,031,894. The disclosure for this sale can be found here. Insiders sold 41,285 shares of company stock valued at $10,331,003 in the last three months. 1.60% of the stock is currently owned by insiders.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.